

Intrasense announces the co-option of a new director and the appointment of a new Chairman of its Board of Directors

Montpellier, France, May 25, 2023, 5:45 CET

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, announces the co-option of a new director to the Board, also appointed Chairman of the Board.

In accordance with the investment agreement signed on January 11, 2023 between Intrasense and Guerbet (the "**Investment Agreement**"), the Board of Directors, meeting on May 24, 2023, approved the co-option of a new director, François Nicolas, to the Intrasense Board of Directors. François Nicolas, Senior Vice President Research, Development and Innovation and Chief Digital Officer of the Guerbet Group, has been co-opted as a director to replace Nicolas Reymond, who has resigned.

Nicolas Reymond was confirmed as Group Chief Executive Officer by the Board of Directors, which thanked him for his active contribution since his appointment in 2018.

Michèle Lesieur, whose commitment was praised by the Board of Directors, has resigned from her position as Chairman of the Board of Directors, a position she has held since 2020, and continues as an independent director of Intrasense. François Nicolas has been appointed Chairman of the Intrasense Board of Directors, replacing Michèle Lesieur.

François Nicolas obtained an engineering degree in 1993 and a doctorate in physics in 1997, both from Ecole Polytechnique in France. He spent 17 years with GE Healthcare in various countries (France, USA and UK), with increasing responsibilities in product development, mainly for interventional X-ray systems, and in business development for neurological PET imaging. François Nicolas then spent 3 years at Sanofi between 2014 and 2017 as Vice President of Integrated Care for Diabetes. He joined Guerbet in 2017 to create a new business line for AI solutions in radiology and with a scope now extended to all R&D.

The Board of Directors is now made up of François Nicolas (representing Guerbet, majority shareholder), Michèle Lesieur (independent director), Anne Larpin (independent director) and Patrice Rullier (independent director), varied profiles strongly committed to supporting Intrasense in its value creation policy.

The appointment of two new directors representing the Guerbet Group will be submitted to shareholders for approval at the next Intrasense Annual General Meeting to be held on June 30, 2023, in accordance with the Investment Protocol.

The ratification of François Nicolas' appointment by co-optation and the renewal of his directorship will also be submitted for shareholder approval at the next Intrasense Annual General Meeting.

Nicolas Reymond, CEO of Intrasense, comments: *"We are very pleased with the co-optation of François Nicolas as a director and his appointment as Chairman of the Board of Directors. This development strengthens the support of our new reference shareholder through an active role in Intrasense's governance. Together, we will continue to implement our growth strategy, focusing on innovation within our product lines and on the commercial growth of our solutions in our various markets"*.

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device, Myrian®, a software platform that facilitates and secures diagnosis, decision making and therapeutic follow-up.

Thanks to Myrian®, more than 1,000 healthcare institutions over 40 countries benefit from a single, integrated platform for reading all types of images (MRI, CT, etc.). Enriched with expert clinical applications for specific pathologies, Myrian® offers a universal medical

image processing solution that can be integrated into all healthcare information systems. Intrasense has 55 employees, including 20 dedicated to Research and Development. Labelled as an "innovative company" by the BPI, it has invested more than 12 million euros in Research and Development since its creation.

More information on www.intrasense.fr .

Intrasense

Salomé Sylvestre
Communications Officer
Phone: +334 67 13 01 30

investisseurs@intrasense.fr

NewCap

Thomas Grojean
Financial Communication and IR
Phone: +331 44 71 20 40

intrasense@newcap.eu